Document is current
Any future updates will be listed below
-
Authors
Wunderle, Marius
Ruebner, Matthias
Häberle, Lothar
Schwenke, Eva
Hack, Carolin C.
Bayer, Christian M.
Koch, Martin C.
Schwitulla, Judith
Schulz-Wendtland, Ruediger
Kozieradzki, Ivona
Lux, Michael P.
Beckmann, Matthias W.
Jud, Sebastian M.
Penninger, Josef M. https://orcid.org/0000-0002-8194-3777
Schneider, Michael O.
Fasching, Peter A. https://orcid.org/0000-0003-4885-8471
-
Funding
Funding for this research was provided by:
ERC Advanced Grant on RANK/RANKL in cancer.
The Department of Gynecology and Obstetrics of Friedrich Alexander University of Erlangen-Nuremberg conducts research with research grants from Novartis and Biontech.
- License Information
-
More Information
Article History
Received: 1 May 2019
Accepted: 3 March 2020
First Online: 20 March 2020
Competing interests
: C.C.H. received honoraria from Roche. M.C.K. received honoraria from Roche, NCO, and Valley Electronics AG, he participated on advisory boards for Hexal/Sandoz, Medac, and Roche, and he has stock ownership of Roche and Bayer. M.P.L. received honoraria from Pfizer, Roche, MSD, Hexal, Novartis. AstraZeneca, Celgene, Eisai, and Medac for advisory boards, lectures, and travel support. J.M.P. received an ERC Advanced Grant on RANKL/RANK in cancer and holds a patent on RANKL inhibition in breast cancer. P.A.F. received honoraria from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, TEVA, AstraZeneca, Puma, Eisai, MSD, and Myelo Therapeutics, and his institution conducts research with research grants from Novartis and Biontech. All remaining authors declare no competing interests.
